Immunotherapy, pembrolizumab, is active against mucosal melanoma tumors
Sunday, January 29, 2017 - 21:31
in Health & Medicine
Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma.